{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04971447",
      "OrgStudyIdInfo": {
        "OrgStudyId": "21.03.30.69624"
      },
      "Organization": {
        "OrgFullName": "Central Hospital, Nancy, France",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Extracellular Vesicles and Endothelial Function in Transgender Subjects",
      "OfficialTitle": "Effects of Plasma Extracellular Vesicles on Endothelial Function in Transgender Subjects",
      "Acronym": "Evinge"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2021",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "September 2021",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "September 2023",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "January 2024",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "July 12, 2021",
      "StudyFirstSubmitQCDate": "July 12, 2021",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 21, 2021",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "July 12, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 21, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Central Hospital, Nancy, France",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Cardiovascular diseases are the leading cause of mortality. In women, the prevalence of cardiovascular diseases is lower and the presentation of coronary events often atypical. The lack of evidence is related in part to the methodology of studies not considering sex as an essential biological variable. Hormonal treatment is prescribed in transgender subjects to promote the development of sexual characteristics of the desired sex. Early cardiovascular effects of hormonal treatment have been reported in transgender men, while long-term mortality is higher in transgender women. The aim of this project is to study the effects of gender affirming hormonal treatment on arterial stiffness in young transgender subjects followed at the University Hospital of Nancy."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Transgenderism"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "transgender persons",
          "hormonal therapy"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Not Applicable"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "136",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Group: transgender men",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: gender affirming hormonal treatment in transgender men"
              ]
            }
          },
          {
            "ArmGroupLabel": "Groupe: control cis-gender women",
            "ArmGroupType": "No Intervention"
          },
          {
            "ArmGroupLabel": "Group: transgender women",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: gender affirming hormonal treatment in transgender women"
              ]
            }
          },
          {
            "ArmGroupLabel": "Groupe: control cis-gender men",
            "ArmGroupType": "No Intervention"
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "gender affirming hormonal treatment in transgender men",
            "InterventionDescription": "testosterone enanthate",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group: transgender men"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "gender affirming hormonal treatment in transgender women",
            "InterventionDescription": "GnRH agonists + estrogen",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group: transgender women"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "pulse wave velocity",
            "PrimaryOutcomeDescription": "measurement of arterial stiffness",
            "PrimaryOutcomeTimeFrame": "24 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nTrasgender subject demanding gender affirming hormonal therapy\n\nExclusion Criteria:\n\nPrevious hormonal therapy\nPregnancy\nChronic disease\nCancer\nObesity\nDrug abuse\nAlcohol\nTabac",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "GenderBased": "Yes",
      "GenderDescription": "yes",
      "MinimumAge": "18 Years",
      "MaximumAge": "49 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M15661",
            "InterventionBrowseLeafName": "Testosterone",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M7268",
            "InterventionBrowseLeafName": "Estrogens",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M10903",
            "InterventionBrowseLeafName": "Methyltestosterone",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M223447",
            "InterventionBrowseLeafName": "Testosterone undecanoate",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M223457",
            "InterventionBrowseLeafName": "Testosterone enanthate",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M235006",
            "InterventionBrowseLeafName": "Testosterone 17 beta-cypionate",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          }
        ]
      }
    }
  }
}